Comment on "Predictors and Management of Loss of Response to Vedolizumab in Inflammatory Bowel Disease"
Inflamm Bowel Dis
.
2019 Apr 11;25(5):e59.
doi: 10.1093/ibd/izy273.
Authors
Renske W M Pauwels
1
,
Annemarie C de Vries
1
,
C Janneke van der Woude
1
Affiliation
1
Erasmus University Medical Center, Rotterdam, the Netherlands.
PMID:
31222304
DOI:
10.1093/ibd/izy273
No abstract available
Publication types
Letter
Comment
MeSH terms
Antibodies, Monoclonal, Humanized
Humans
Inflammatory Bowel Diseases*
Substances
Antibodies, Monoclonal, Humanized
vedolizumab